Skip to content
value.today

Lexaria Bioscience Corp. is listed today as Lexaria Bioscience Corp.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 7 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Lexaria Bioscience Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2025$4 MPrivate placement after listing$2 to $10 million

Lexaria Bioscience Corp.: Private sale, Dec 2025

Investors in this round

5 investors had bought by the notice of Dec 19, 2025: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$245,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • John Docherty · Executive Officer, Director
  • Michael Shankman · Executive Officer
  • Richard Christopher · Executive Officer, Director
  • ALBERT Edward REESE · Director
  • Bal Edward Bhullar · Director
  • Christopher Bunka · Director
  • Nicholas Baxter · Director
  • William Edward McKechnie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. WAINWRIGHT & CO. (CRD 375) · New York, New YorkSold in FL, IL, NY

Remarks in the notice

  • On fees: “Sales commission represents 7% of the gross proceeds received from the sale of registered shares and unregistered warrants”
  • On the amounts: “Offering amount represents gross proceeds from the sale of shares registered under an S-3 Registration Statement and the associated non-registered warrants”

Signed by Richard Christopher, Ceo. Source: SEC Form D, newest notice filed Dec 19, 2025. Read the notice at the SEC.

optionsSEC
Sep 2025$4 MPrivate placement after listing$2 to $10 million

Lexaria Bioscience Corp.: Private sale, Sep 2025

Investors in this round

5 investors had bought by the notice of Oct 1, 2025: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$280,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • John Docherty · Executive Officer, Director
  • Michael Shankman · Executive Officer
  • Richard Christopher · Executive Officer, Director
  • Albert Edward Reese · Director
  • Bal Edward Bhullar · Director
  • Christopher Bunka · Director
  • Nicholas Baxter · Director
  • William Edward McKechnie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. WAINWRIGHT & CO. (CRD 375) · New York, New YorkSold in IL, NY, and outside the US

Remarks in the notice

  • On fees: “Commission represents 7% of the offering amount, including for the registered shares that form part of the combined offering of 1 registered share and 1 unregistered warrant”

Signed by Richard Christopher, Ceo. Source: SEC Form D, newest notice filed Oct 1, 2025. Read the notice at the SEC.

optionsSEC
Oct 2024$5 MPrivate placement after listing$2 to $10 million

Lexaria Bioscience Corp.: Private sale, Oct 2024

Investors in this round

1 investor had bought by the notice of Oct 16, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$350,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • John Docherty · Executive Officer, Director
  • Michael Shankman · Executive Officer
  • Richard Christopher · Executive Officer
  • Albert Reese · Director
  • Catherine Turkel · Director
  • Christopher Bunka · Director
  • Nicholas Baxter · Director
  • Ted Mckechnie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. WAINWRIGHT & CO. (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Commission represents 7% of the offering amount”
  • On the amounts: “Offering Amount is for the shares that were issued as registered securities, the unregistered warrants from part of the offering”

Signed by Richard Christopher, Ceo. Source: SEC Form D, newest notice filed Oct 16, 2024. Read the notice at the SEC.

optionsSEC
Feb 2024$4 MPrivate placement after listing$2 to $10 million

Lexaria Bioscience Corp.: Private sale, Feb 2024

Investors in this round

2 investors had bought by the notice of Feb 16, 2024: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$222,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Christopher Bunka · Executive Officer, Director
  • John Docherty · Executive Officer, Director
  • Albert Reese · Director
  • Catherine Turkel · Director
  • Nicholas Baxter · Director
  • Ted Mckechnie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. WAINWRIGHT & CO. (CRD 375) · New York, New YorkSold in IL, NY

Signed by Christopher Bunka, Ceo. Source: SEC Form D, newest notice filed Feb 16, 2024. Read the notice at the SEC.

optionsSEC
Oct 2023$2 MPrivate placement after listingUnder $2 million

Lexaria Bioscience Corp.: Private sale, Oct 2023

Investors in this round

1 investor had bought by the notice of Oct 4, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$109,879
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Christopher Bunka · Executive Officer, Director
  • John Docherty · Executive Officer, Director
  • Albert Reese · Director
  • Catherine Turkel · Director
  • Nicholas Baxter · Director
  • Ted Mckechnie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MAXIM GROUP LLC (CRD 120708) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “"Maxim Group LLC (""Maxim""), acted as the placement agent in connection with the offering. Maxim received an aggregate fee equal to 5% of the gross proceeds of the offering."”
  • On the amounts: “The combined effective offering price of each warrant which was combined with a registered share of common stock or a pre-funded warrant in lieu was $0.97, or aggregate gross proceeds of approximately $1.5 million”

Signed by Christopher Bunka, Ceo. Source: SEC Form D, newest notice filed Oct 4, 2023. Read the notice at the SEC.

optionsSEC
Dec 2021$1 MPrivate placement after listingUnder $2 million

Lexaria Bioscience Corp.: Private sale, Dec 2021

Investors in this round

1 investor had bought by the notice of Dec 20, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Christopher Bunka · Executive Officer, Director
  • Gregory Downey · Executive Officer
  • John Docherty · Executive Officer, Director
  • Albert Reese · Director
  • Nicholas Baxter · Director
  • Ted Mckechnie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Chris Bunka, Chief executive officer. Source: SEC Form D, newest notice filed Dec 20, 2021. Read the notice at the SEC.

equitySEC
May 2020$2 MPrivate placement after listing$2 to $10 million

Lexaria Bioscience Corp.: Private sale, May 2020

Investors in this round

21 investors had bought by the notice of May 13, 2020: 20 accredited, 1 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$151,623
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Allan Spissinger · Executive Officer
  • Christopher Bunka · Executive Officer, Director
  • John Docherty · Executive Officer, Director
  • Brian Quigley · Director
  • Nicholas Baxter · Director
  • Ted McKechnie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Bradley Woods & Co. Ltd. (CRD 13660) · New York, New YorkSold in CA, CT, IL, NY, PA, WI, and outside the US

Remarks in the notice

  • On fees: “In addition to the sales commission,the Company issued to the placement agent and its designees Warrants to purchase up to 649,123 shares of common stock and shall, subject to certain exceptions, pay 8% of the proceeds received from warrant exercises.”

Signed by Christopher Bunka, Ceo. Source: SEC Form D, newest notice filed May 13, 2020. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Lexaria Bioscience Corp., its revenue in fiscal 2025 came from these product and service lines: IP Licensing $700,000 (99%), B2B $10,000 (1%).

    Annual report (SEC XBRL) · Aug 2025

  • Lexaria Bioscience Corp. had revenue between $5 million and $25 million when it filed its newest notice of a funding round (Dec 2025).

    SEC Form D (revenue range) · Dec 2025

  • Revenue range over time, as stated in its notices: revenue of up to $1 million in 2021; revenue of up to $1 million in 2023; revenue between $5 million and $25 million in 2024; revenue between $5 million and $25 million in 2025.

    SEC Form D (revenue range) · Dec 2025

  • The industry group it chose in its notices: Other.

    SEC Form D · Dec 2025

Products and services#

No products or services of Lexaria Bioscience Corp. are on record.

Investors#

No investor of Lexaria Bioscience Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Lexaria Bioscience Corp. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Lexaria Bioscience Corp.
NameRoleNamed in
John DochertyExecutive officerDec 2025
Michael ShankmanExecutive officerDec 2025
Richard ChristopherExecutive officerDec 2025
Christopher BunkaExecutive officerFeb 2024
Gregory DowneyExecutive officerDec 2021
Allan SpissingerExecutive officerMay 2020
ALBERT Edward REESEDirectorDec 2025
Bal Edward BhullarDirectorDec 2025
Christopher BunkaDirectorDec 2025
John DochertyDirectorDec 2025
Nicholas BaxterDirectorDec 2025
Richard ChristopherDirectorDec 2025
William Edward McKechnieDirectorDec 2025
Albert Edward ReeseDirectorOct 2025
Albert ReeseDirectorOct 2024
Catherine TurkelDirectorOct 2024
Ted MckechnieDirectorOct 2024
Brian QuigleyDirectorMay 2020
Ted McKechnieDirectorMay 2020

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.